Zimmer Biomet Q2 Sales Rise 4.8%, Raises Full-Year Guidance
ZBH sits 23% above its 52-week low of $79.12.
Summary
Zimmer Biomet reported Q2 2026 net sales of $2.177 billion, up 4.8% reported, and raised full-year revenue and adjusted EPS guidance. Adjusted EPS of $2.07 was flat versus last year.
Key Events · Earnings and Guidance · ZBH
-
Q2 Revenue Beats, Organic Growth 4.0%
Net sales of $2.177 billion increased 4.8% reported and 4.0% on an organic constant currency basis, driven by hips (+5.1%) and S.E.T. (+3.4%).
-
Full-Year Guidance Raised
2026 revenue growth guidance raised to 3.9%-4.9% (from 2.5%-4.5%) and adjusted EPS to $8.47-$8.59 (from $8.40-$8.55), reflecting strong first-half momentum.
-
Adjusted EPS Flat at $2.07
Adjusted diluted EPS of $2.07 was consistent with the prior year period, as higher sales were offset by increased operating expenses.
-
Strong Cash Flow Supports Buyback
Generated $447.9 million in operating cash flow and $308.3 million in free cash flow in Q2; the company repurchased $500.8 million of stock in the first half, on track toward its $1 billion target.
Analysis · ZBH · Industrial Applications And Services
Zimmer Biomet delivered a solid second quarter with organic revenue growth of 4.0% and raised its full-year revenue and adjusted EPS outlook. The guidance raise signals confidence in underlying demand and the commercial transformation, though adjusted EPS of $2.07 was flat year-over-year. Strong cash flow supports the ongoing $1 billion buyback program.
At the time of this filing, ZBH was trading at $97.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $18.5B. The 52-week trading range was $79.12 to $108.29. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.